Catalent to manufacture Moderna's personalized cancer vaccine for Ph I/II studies

By Melissa Fassbender

- Last updated on GMT

Clinical study of Moderna's mRNA personalized cancer vaccine is expected to begin in 2017. (Image: Catalent)
Clinical study of Moderna's mRNA personalized cancer vaccine is expected to begin in 2017. (Image: Catalent)

Related tags Vaccine

Catalent has entered into an agreement with Moderna Therapeutics to support the company’s proprietary production process.

Mike Riley, VP and General Manager of Catalent​ Biologics confirmed that the company will be providing cGMP manufacturing of Moderna’s mRNA personalized cancer vaccine for phase I/II clinical studies.

According to the company, clinical study of the vaccine is expected to begin in 2017.

Under the agreement, Catalent will be providing dedicated production capability to accommodate Moderna’s proprietary production process, and support fast turnaround of clinical material​,” Riley told us.

Work will take place at Catalent’s Madison, WI-based facility, which was opened in 2013 to support both flexible cGMP and non-GMP production.

The site features integrated process development and analytical capabilities, including the support of method development, in-process, release and stability testing​,” said Riley.

Additionally, Catalent recently announced an expansion to the facility, which Riley said will create increased capacity for later phase clinical and commercial production.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers